2.Single nucleotide polymorphism of GSTP1 and pathological complete response in locally advanced rectal cancer patients treated with neoadjuvant concomitant radiochemotherapy
Luca NICOSIA ; Giovanna GENTILE ; Chiara REVERBERI ; Giuseppe MINNITI ; Maurizio VALERIANI ; Vitaliana DE SANCTIS ; Luca MARINELLI ; Fabiola CIPOLLA ; Ottavia DE LUCA ; Maurizio SIMMACO ; Mattia F OSTI
Radiation Oncology Journal 2018;36(3):218-226
PURPOSE: Standard treatment for locally advanced rectal cancer consists of neoadjuvant radiochemotherapy with concomitant fluoropyrimidine or oxaliplatin and surgery with curative intent. Pathological complete response has shown to be predictive for better outcome and survival; nevertheless there are no biological or genetic factors predictive for response to treatment. We explored the correlation between the single nucleotide polymorphisms (SNPs) GSTP1 (A313G) and XRCC1 (G28152A), and the pathological complete response and survival after neoadjuvant radiochemotherapy in locally advanced rectal cancer patients. MATERIALS AND METHODS: Genotypes GSTP1 (A313G) and XRCC1 (G28152A) were determined by pyrosequencing technology in 80 patients affected by locally advanced rectal cancer. RESULTS: The overall rate of pathological complete response in our study population was 18.75%. Patients homozygous AA for GSTP1 (A313G) presented a rate of pathological complete response of 26.6% as compared to 8.5% of the AG+GG population (p = 0.04). The heterozygous comparison (AA vs. AG) showed a significant difference in the rate of pathological complete response (26.6% vs. 6.8%; p = 0.034). GSTP1 AA+AG patients presented a 5- and 8-year cancer-specific survival longer than GSTP1 GG patients (87.7% and 83.3% vs. 44.4% and 44.4%, respectively) (p = 0.014). Overall survival showed only a trend toward significance in favor of the haplotypes GSTP1 AA+AG. No significant correlations were found for XRCC1 (G28152A). CONCLUSION: Our results suggest that GSTP1 (A313G) may predict a higher rate of pathological complete response after neoadjuvant radiochemotherapy and a better outcome, and should be considered in a more extensive analysis with the aim of personalization of radiation treatment.
Chemoradiotherapy
;
Genetic Markers
;
Genotype
;
Haplotypes
;
Humans
;
Polymorphism, Single Nucleotide
;
Rectal Neoplasms
3.Response to Letter; Discrimination between Benign and Malignant Post-SARS-CoV-2 Vaccination Lymphadenopathy is Feasible, to Our Article; Axillary Adenopathy in Patients with Recent COVID-19 Vaccination: A New Diagnostic Dilemma
Arwa ASHOOR ; Julie SHEPHARD ; Germana LISSIDINI ; Luca NICOSIA
Korean Journal of Radiology 2022;23(7):775-776
5.Percutaneous laser ablation for benign and malignant thyroid diseases.
Giovanni MAURI ; Luca NICOSIA ; Paolo DELLA VIGNA ; Gianluca Maria VARANO ; Daniele MAIETTINI ; Guido BONOMO ; Gioacchino GIULIANO ; Franco ORSI ; Luigi SOLBIATI ; Elvio DE FIORI ; Enrico PAPINI ; Claudio Maurizio PACELLA ; Luca Maria SCONFIENZA
Ultrasonography 2019;38(1):25-36
Minimally invasive image-guided thermal ablation is becoming increasingly common as an alternative to surgery for the treatment of benign thyroid nodules. Among the various techniques for thermal ablation, laser ablation (LA) is the least invasive, using the smallest applicators available on the market and enabling extremely precise energy deposition. However, in some cases, multiple laser fibers must be used simultaneously for the treatment of large nodules. In this review, the LA technique is described, and its main clinical applications and results are discussed and illustrated.
Laser Therapy*
;
Thyroid Diseases*
;
Thyroid Gland*
;
Thyroid Nodule
;
Ultrasonography